#3641 DOES IBANDRONATE OR CALCIUM AND VITAMIN D MAINTAIN OR IMPROVE BONE MICROARCHITECTURE IN THE FIRST YEAR AFTER KIDNEY TRANSPLANTATION?

Abstract Background and Aims Modern immunosuppressive protocols are associated with less loss of bone mass immediately after kidney transplantation, as compared previous eras. Even so, microarchitecture may still be disturbed due to long-standing uremia, leading fragility fracture susceptibility. Trabecular score (TBS) is a new tool assess trabecular based on standard dual energy X-ray absorptiometry (DXA) lumbar spine images. TBS reflects quality rather than quantity. Studies the effect common anti-fracture strategies in transplant recipients (KTR) scarce. Our aim was investigate different treatments by KTR. Method We analyzed changes potential treatment effects 179 de novo KTR, 118 whom had participated randomized controlled trial[1] evaluating ibandronate (active/placebo) top calcium vitamin D first year transplantation. Trial participants were 61 patients transplanted same time-period, meeting study inclusion criteria, but receiving no specific bone-directed treatment. Correlations between BMD investigated. used ANOVA ANCOVA adjustment for baseline values evaluate with/without concomitant 12 months Results Mean increased all groups from transplantation (2.1% ibandronate/calcium/vitamin D, 2.7% calcium/vitamin 3.4% treatment). Adjusting TBS, there significant differences at months, neither overall comparison (p = 0.377) nor when comparing pairwise. The correlation weak (r 0.170, p 0.02) baseline, change not significantly correlated any groups. Conclusion In group KTR reasonably well-preserved mass, it does appear that one or affects measured TBS. found surprisingly over period, indicating these measurements reflect aspects integrity metabolism. This strengthens view focus should identifying high risk time could benefit anti-resorptive therapy.